Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.

CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. CD101 has potent in vitro activity and in vivo efficacy against a broad range of Candida and Aspergillus species. The primary objective of two randomized, double-blind, placebo-controlled, dose-escalation studies in healthy adults was to determine the safety and tolerability of CD101 IV.

Source: The Aspergillus Website - updates - January 23, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news